Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis

PURPOSE: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the standard chemotherapy in diffuse large B-cell lymphoma (DLBCL) patients. Although febrile neutropenia (FN) is the major toxicity of this regimen, non-neutropenic fever (NNF) becomes an emerging issue....

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Silvia, Kang, Cheol-In, Chung, Doo Ryeon, Peck, Kyong Ran, Kim, Won Seog, Kim, Seok Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506109/
https://www.ncbi.nlm.nih.gov/pubmed/25648098
http://dx.doi.org/10.4143/crt.2014.034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506109/
https://www.ncbi.nlm.nih.gov/pubmed/25648098
http://dx.doi.org/10.4143/crt.2014.034

Ejemplares similares